Kappa and delta opioid receptor signaling is augmented in the failing heart

Journal of Molecular and Cellular Cardiology

Volumn 47, Issue 4, 2009, Pages 493-503

  Bolte, Craig ^a   Newman, Gilbert ^a   Schultz, Jo El J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac physiology; Cardiomyopathy; G protein signaling; Opioids; Work performing heart

Indexed keywords

CALCIUM ION; CYCLIC AMP; DELTA OPIATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; PERTUSSIS TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE EXACERBATION; HAMSTER; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; INOTROPISM; ISOLATED HEART; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANIMALS; CALCIUM SIGNALING; CARDIOMEGALY; CARDIOMYOPATHIES; CRICETINAE; CYCLIC AMP; FENTANYL; HEART FAILURE; HEART FUNCTION TESTS; HETEROTRIMERIC GTP-BINDING PROTEINS; MYOCARDIAL CONTRACTION; OPIOID PEPTIDES; PERTUSSIS TOXIN; QUINOLINES; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; SIGNAL TRANSDUCTION; SYSTOLE;

CRICETINAE;

EID: 69249229702     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.06.016     Document Type: Article

References (40)

1. Jurynec J. Hypertrophic cardiomyopathy: a review of etiology and treatment. J. Cardiovasc. Nurs. 22 1 (2007) 65-73 quiz 74-5
2. Tsubata S., Bowles K.R., Vatta M., Zintz C., Titus J., Muhonen L., et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J. Clin. Invest. 106 5 (2000) 655-662
3. Kawada T., Nakatsuru Y., Sakamoto A., Koizumi T., Shin W.S., Okai-Matsuo Y., et al. Strain- and age-dependent loss of sarcoglycan complex in cardiomyopathic hamster hearts and its re-expression by delta-sarcoglycan gene transfer in vivo. FEBS Lett. 458 3 (1999) 405-408
4. Bajusz E. Hereditary cardiomyopathy: a new disease model. Am. Heart J. 77 5 (1969) 686-696
5. Kasper E., Ventura C., Ziman B.D., Lakatta E.G., Weisman H., and Capogrossi M.C. Effect of U-50,488H on the contractile response of cardiomyopathic hamster ventricular myocytes. Life Sci. 50 26 (1992) 2029-2035
6. Sen L.Y., O'Neill M., Marsh J.D., and Smith T.W. Inotropic and calcium kinetic effects of calcium channel agonist and antagonist in isolated cardiac myocytes from cardiomyopathic hamsters. Circ. Res. 67 3 (1990) 599-608
7. Barron B.A. Cardiac opioids. Proc. Soc. Exp. Biol. Med. 224 1 (2000) 1-7
8. Ventura C., Gianfranco P., and Bruna T. Opioid peptide gene expression in the myocardial cell. TCM 8 3 (1998) 102-110
9. Feuerstein G., and Siren A.L. The opioid peptides. A role in hypertension. Hypertension 9 6 (1987) 561-565
10. Ventura C., Pintus G., Fiori M.G., Bennardini F., Pinna G., and Gaspa L. Opioid peptide gene expression in the primary hereditary cardiomyopathy of the Syrian hamster. I. Regulation of prodynorphin gene expression by nuclear protein kinase C. J. Biol. Chem. 272 10 (1997) 6685-6692
11. Ouellette M., and Brakier-Gingras L. Increase in the relative abundance of preproenkephalin A messenger RNA in the ventricles of cardiomyopathic hamsters. Biochem. Biophys. Res. Commun. 155 1 (1988) 449-454
12. Bolte C., Newman G., and Schultz Jel J. Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac kappa-opioid receptor stimulation. Am. J. Physiol, Heart Circ. Physiol. 296 4 (2009) H967-H975
13. Knapp R.J., Landsman R., Waite S., Malatynska E., Varga E., Haq W., et al. Properties of TAN-67, a nonpeptidic delta-opioid receptor agonist, at cloned human delta- and mu-opioid receptors. Eur. J. Pharmacol. 291 2 (1995) 129-134
14. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G.I., et al. Pharmacological characterization of the cloned kappa-, delta-, and mu- opioid receptors. Mol. Pharmacol. 45 2 (1994) 330-334
15. Zimlichman R., Gefel D., Eliahou H., Matas Z., Rosen B., Gass S., Ela C., et al. Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats. Circulation 93 5 (1996) 1020-1025
16. Hefti M.A., Harder B.A., Eppenberger H.M., and Schaub M.C. Signaling pathways in cardiac myocyte hypertrophy. J. Mol. Cell. Cardiol. 29 11 (1997) 2873-2892
17. Clark M.J., Harrison C., Zhong H., Neubig R.R., and Traynor J.R. Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways. J. Biol. Chem. 278 11 (2003) 9418-9425
18. Standifer K.M., and Pasternak G.W. G proteins and opioid receptor-mediated signalling. Cell. Signal. 9 3-4 (1997) 237-248
19. Ventura C., Spurgeon H., Lakatta E.G., Guarnieri C., and Capogrossi M.C. Kappa and delta opioid receptor stimulation affects cardiac myocyte function and Ca2+ release from an intracellular pool in myocytes and neurons. Circ. Res. 70 1 (1992) 66-81
20. Ventura C., Muscari C., Spampinato S., Bernardi P., and Caldarera C.M. Effects of naloxone on the mechanical activity of isolated rat hearts perfused with morphine or opioid peptides. Peptides 8 4 (1987) 695-699
21. Schultz J.E., Hsu A.K., Barbieri J.T., Li P.L., and Gross G.J. Pertussis toxin abolishes the cardioprotective effect of ischemic preconditioning in intact rat heart. Am. J. Physiol. 275 2 Pt 2 (1998) H495-H500
22. Schultz J.E., and Gross G.J. Opioids and cardioprotection. Pharmacol. Ther. 89 2 (2001) 123-137
23. Fryer R.M., Wang Y., Hsu A.K., and Gross G.J. Essential activation of PKC-delta in opioid-initiated cardioprotection. Am. J. Physiol, Heart Circ. Physiol. 280 3 (2001) H1346-H1353
24. Bian J.S., Zhang W.M., Pei J.M., and Wong T.M. The role of phosphodiesterase in mediating the effect of protein kinase C on cyclic AMP accumulation upon kappa-opioid receptor stimulation in the rat heart. J. Pharmacol. Exp. Ther. 292 3 (2000) 1065-1070
25. Peart J.N., and Gross G.J. Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways. Am. J. Physiol, Heart Circ. Physiol. 291 4 (2006) H1746-H1753
26. Angers S., Salahpour A., and Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 409-435
27. Jordan B.A., and Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399 6737 (1999) 697-700
28. Huang P., Xu W., Yoon S.I., Chen C., Chong P.L., and Liu-Chen L.Y. Cholesterol reduction by methyl-beta-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cells. Biochem. Pharmacol. 73 4 (2007) 534-549
29. Hailstones D., Sleer L.S., Parton R.G., and Stanley K.K. Regulation of caveolin and caveolae by cholesterol in MDCK cells. J. Lipid Res. 39 2 (1998) 369-379
30. Pogue D.H., Moravec C.S., Roppelt C., Disch C.H., Cressman M.D., and Bond M. Effect of lovastatin on cholesterol content of cardiac and red blood cell membranes in normal and cardiomyopathic hamsters. J. Pharmacol. Exp. Ther. 273 2 (1995) 863-869
31. Hnasko R., and Lisanti M.P. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol. Interv. 3 8 (2003) 445-464
32. Fontana F., Bernardi P., Pich E.M., Capelli M., Bortoluzzi L., Spampinato S., et al. Relationship between plasma atrial natriuretic factor and opioid peptide levels in healthy subjects and in patients with acute congestive heart failure. Eur. Heart J. 14 2 (1993) 219-225
33. Yatani A., Imai N., Himura Y., Suematsu M., and Liang C.S. Chronic opiate-receptor inhibition in experimental congestive heart failure in dogs. Am. J. Physiol. 272 1 Pt 2 (1997) H478-H484
34. Redfern C.H., Degtyarev M.Y., Kwa A.T., Salomonis N., Cotte N., Nanevicz T., et al. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 97 9 (2000) 4826-4831
35. Bers D.M., and Despa S. Cardiac myocytes Ca2+ and Na+ regulation in normal and failing hearts. J. Pharmacol. Sci. 100 5 (2006) 315-322
36. Aitchison K.A., Baxter G.F., Awan M.M., Smith R.M., Yellon D.M., and Opie L.H. Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioning. Basic Res. Cardiol. 95 1 (2000) 1-10 discussion 11
37. Johnson M.J., McDonagh T.A., Harkness A., McKay S.E., and Dargie H.J. Morphine for the relief of breathlessness in patients with chronic heart failure-a pilot study. Eur. J. Heart Fail. 4 6 (2002) 753-756
38. Pepe S., Xiao R.P., Hohl C., Altschuld R., and Lakatta E.G. 'Cross talk' between opioid peptide and adrenergic receptor signaling in isolated rat heart. Circulation 95 8 (1997) 2122-2129
39. Gibofsky A., and Barkin R.L. Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesic. Am. J. Ther. 15 3 (2008) 241-255
40. Antman E.M., Bennett J.S., Daugherty A., Furberg C., Roberts H., and Taubert K.A. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 12 (2007) 1634-1642